

Sugammadex Compared to Neostigmine for Reversal of Neuromuscular Block in Patients Undergoing Kidney Transplantation. A Retrospective Cohort, Case-Control Study.

Michele Carron (✉ dr.michele.carron@gmail.com)

University of Padova: Università degli Studi di Padova <https://orcid.org/0000-0001-5104-4124>

Giulio Adreata

University of Padova: Università degli Studi di Padova

Elisa Pesenti

University of Padova: Università degli Studi di Padova

Alessandro De Cassai

Azienda Ospedale Università Padova

Paolo Feltracco

University of Padova: Università degli Studi di Padova

Federico Linassi

Ca' Foncello Treviso Regional Hospital

Massimo Sergi

Azienda Ospedale Università Padova

Caterina Di Bella

University of Padova: Università degli Studi di Padova

Marianna Di Bello

University of Padova: Università degli Studi di Padova

Flavia Neri

University of Padova: Università degli Studi di Padova

Cristina Silvestre

Azienda Ospedale Università Padova

Lucrezia Furian

University of Padova: Università degli Studi di Padova

Paolo Navalesi

University of Padova: Università degli Studi di Padova

Keywords: Anesthesia, Neuromuscular block, Sugammadex, Neostigmine, End-stage renal disease, Kidney transplantation.

Posted Date: March 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-308161/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: The impact of sugammadex in patients with end-stage renal disease undergoing kidney transplantation is still far from being defined. The aim of the study is to compare sugammadex to neostigmine for reversal of rocuronium- and cisatracurium-induced neuromuscular block (NMB), respectively, in patients undergoing kidney transplantation.

Methods: A retrospective, observational study was performed. A total of 350 patients undergoing kidney transplantation, equally divided between a sugammadex group (175 patients) and a neostigmine group (175 patients), were considered. Postoperative kidney function, evaluated by monitoring of serum creatinine and urea and estimated glomerular filtration rate (eGFR), was the endpoint. Other endpoints were anaesthetic and surgical times, post-anaesthesia care unit length of stay, postoperative intensive care unit admission, and recurrent NMB or complications.

Results: No significant differences in patient or, with the exception of drugs involved in NMB management, anaesthetic and surgical characteristics were observed between the two groups. Serum creatinine (median [interquartile range]: 596.0 [478.0-749.0] vs 639.0 [527.7-870.0] $\mu\text{mol/L}$, $p=0.0128$) and serum urea (14.9 [10.8-21.6] vs 17.1 [13.1-22.0] mmol/L , $p=0.0486$) were lower, while eGFR (8.0 [6.0-11.0] vs 8.0 [6.0-10.0], $p=0.0473$) was higher in the sugammadex group than in the neostigmine group after surgery. The sugammadex group showed significant lower incidence of postoperative severe hypoxemia (0.6% vs 6.3%, $p=0.006$), shorter PACU stay (70 [60-90] min vs 90 [60-105] min, $p<0.001$), and reduced ICU admissions (0.6% vs 8.0%, $p=0.001$).

Conclusions: Compared to neostigmine for reversal of NMB, sugammadex resulted in a better recovery profile in patients undergoing kidney transplantation.

Introduction

Kidney transplantation represents the best option to improve survival and quality of life in patients with end-stage renal disease (ESRD) (Kellar et al. 2015).

The surgical procedure of kidney transplantation is generally performed under general anaesthesia and presents significant challenges for the anaesthesiologist (Martinez et al. 2013). A careful anaesthetic approach is highly recommended to improve outcomes (Martinez et al. 2013; De Gasperi et al. 2014; Mittel et al. 2017; Wagener et al. 2020). The management of neuromuscular block (NMB) deserves particular attention (Martinez et al. 2013; Mittel et al. 2017) in order to reduce the incidence of complications due to postoperative residual NMB (De Gasperi et al. 2014; Miskovic et al. 2017). Patients receiving, compared to those not receiving, neuromuscular blocking agents (NMBAs) during general anaesthesia are at significantly increased risk of postoperative respiratory complications (adjusted odds ratio [aOR]: 1.86) (Kirmeier et al. 2019). Benzylisoquinolinium compounds, such as cisatracurium, and aminosteroid NMBAs, such as rocuronium, are commonly used during general anaesthesia for kidney transplantation. Cisatracurium seems to benefit from certain favour among anaesthesiologists because it

is inactivated by Hofmann elimination and hydrolysis by esterases independent of renal function, whereas rocuronium is characterized by organ-independent elimination. However, both are associated with slightly prolonged duration of action and require careful neuromuscular function monitoring for safe recovery at the end of surgery (Della Rocca et al. 2003; Martinez et al. 2013; Mittel et al. 2017). While proper neuromuscular function monitoring is crucial in avoiding postoperative complications, particularly respiratory complications (Blobner et al. 2020), the choice of reversal drug seems to be no less important (Kheterpal et al. 2020). Compared to neostigmine, an acetylcholinesterase inhibitor traditionally used for reversal of NMB, the use of sugammadex, a modified γ -cyclodextrin developed for the reversal of NMB induced by aminosteroid NMBAs, particularly rocuronium, was associated with a significant lower incidence of major pulmonary complications (Kheterpal et al. 2020).

Sugammadex is a highly hydrophilic drug and acts in the plasma by encapsulating and inactivating unbound rocuronium to form a 1:1 water-soluble complex. Urinary excretion is the main route of elimination of sugammadex and the sugammadex-rocuronium complex. At this time, sugammadex administration is not recommended by the manufacturer for subjects with severe renal impairment (creatinine clearance [CrCl] < 30 mL/min), including those undergoing standard forms of dialysis (EMA 2021).

The safety profile of sugammadex observed in clinical studies involving subjects with severe renal impairment (Staals et al. 2008; de Souza et al. 2015) encouraged its use in clinical practice in patients with ESRD (Adams et al. 2020; Peredes et al. 2020), particularly in those undergoing kidney transplant (Unterbuchner et al. 2016; Ono et al 2018; Arslantas et al. 2019; Adams et al. 2020; Vargas et al. 2020). However, only retrospective analyses including reports (Unterbuchner et al. 2016) or small cohorts of patients are available in the literature (Ono et al 2018; Arslantas et al. 2019; Adams et al. 2020; Vargas et al. 2020)). Furthermore, no data exist on the use of sugammadex administered for reversal of deep NMB in patients undergoing kidney transplantation.

So, the aim of our study is to evaluate the impact of sugammadex, given at recommended doses for reversal of a moderate or deep rocuronium-induced NMB, compared to neostigmine, administered for reversal of moderate cisatracurium-induced NMB, on renal function in a large cohort of patients undergoing kidney transplantation.

Materials And Methods

Ethical statement and study approval

All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. STROBE recommendations for cohort, case-control studies were followed.

This retrospective observational study was approved by our Institutional Review Board (Ethics Committee in Clinical Research-CESC of Padova, Italy, prot.n.42587, 16 July 2020), which waived the requirement to

obtain patients' written informed consent (the data were analysed retrospectively and anonymously).

Patients

A total of 350 patients with ESRD undergoing kidney transplantation at our hospital were evaluated. Patients were recruited consecutively until the sample size was achieved.

The anaesthesia and medical records and the information system's computer database were used to retrieve data about all patients (age ≥ 18 years) with ESRD who received sugammadex or neostigmine to reverse rocuronium- or cisatracurium-induced NMB, respectively, during inhalational or intravenous anaesthesia for kidney transplantation. Each anaesthesia and medical record were reviewed for preoperative, intraoperative, and postoperative data up to 5 days after surgery. Patient demographics, comorbidities (e.g., history of neurological, respiratory, cardiac, abdominal, and metabolic disease), perioperative data including kidney function (serum creatinine and urea, estimated glomerular filtration rate [eGFR]), and postoperative events were considered.

Standard monitoring was adopted, including deep anaesthesia and neuromuscular function monitoring. All patients received antibiotic prophylaxis (piperacillin 2 g) before surgery, immunosuppression (thymoglobulin 1-1.5 mg/kg or basiliximab 20 mg, and methylprednisolone 500 mg) at the start of surgical procedure, and diuretics (furosemide 100 mg and mannitol 18% 80 mL) during surgery after anastomosis of the renal artery.

After surgery, patients were transferred to the post-anaesthesia care unit (PACU). Level of consciousness, respiratory rate, pulse oximetry, heart rate, and arterial blood pressure were monitored until discharge to the surgical ward. Pain and postoperative nausea and vomiting (PONV) were assessed using a numeric rating scale (NRS) from 0=no pain or nausea to 10=worst possible pain or nausea. Patients were also assessed for clinical evidence of residual or recurrent NMB (e.g., muscle weakness, oxygen desaturation, hypoventilation, critical respiratory event). Patients with a pain NRS score of >3 in the PACU received rescue analgesics (paracetamol 1 g and tramadol 1 mg/kg intravenously). Patients with a PONV NRS score of >3 received a rescue dose of droperidol 0.625-1.25 mg intravenously.

Endpoints

Serum creatinine (primary endpoint) and serum urea and eGFR (secondary endpoints) for monitoring kidney function after surgery for up to 5 postoperative days represented the main endpoints of the study. Other endpoints were anaesthetic and surgical times, length of PACU stay, intensive care unit (ICU) admission, clinical evidence of postoperative respiratory complications (e.g., hypoxemia with peripheral arterial blood oxygen saturation [SaO_2] $<90\%$, critical respiratory event) or cardiovascular event (e.g., stroke, myocardial ischemia, heart failure, hypertension, arrhythmia), PONV NRS score of >3 , pain NRS score of >3 , residual or recurrent NMB, and presence of any other postoperative complications within 24 h after surgery that required treatment.

For respiratory function, gas exchange analysis of arterial blood (pH, arterial partial pressures of oxygen [PaO₂] and carbon dioxide [PaCO₂]) performed 15-20 minutes after tracheal extubation was considered. For cardiac function, heart rate (HR) and systolic (SBP) and diastolic (DBP) arterial blood pressures evaluated 15-20 minutes after tracheal extubation were considered.

Data were collected by researchers without any involvement in the management of patients. They created a dataset with anonymized data for statistical analysis performed by researchers not involved with data collection.

Statistical analysis

The sample size was based on the following assumptions: a mean difference of 44.2 µmol/L of serum creatinine in the first postoperative day between the sugammadex group and the neostigmine group as clinically relevant in the postoperative period (Kork et al. 2015; Gameiro et al. 2018); the type I error equal to 0.05; the type II error equal to 0.2 (power [1-β] = 0.8). Considering these assumptions, the sample size was calculated as 350 patients, equally divided between the sugammadex group (175 patients) and the neostigmine group (175 patients).

Descriptive analysis was used to summarize the sample's characteristics. Normality of distribution of quantitative characteristics was analysed using the Shapiro-Wilk test. Continuous normally distributed variables are expressed as mean ± standard deviation (SD). Median and interquartile range (IQR) values are reported for non-normally distributed variables. The two-tailed Student's t-test or two-tailed Mann-Whitney U test was used to compare normally or non-normally distributed variables, respectively, between the sugammadex and neostigmine groups. Categorical data were reported as absolute number and percentage (%) and compared using χ^2 or Fisher's exact tests. To determine the strength and direction of association between two variables, Bravais-Pearson's correlation test was used for normally distributed variables, and Spearman's rank correlation test was used for non-normally distributed variables. Multiple linear regression analysis was used to examine the relationship between one dependent variable and independent variables. Using the Akaike information criterion, backward and forward stepwise regression was performed to select the best model. Correlation coefficients (CCs), estimate coefficients (ECs), standard errors (SEs), t-values, and p-values were determined. Statistical significance was set at p-values <0.05. All statistical analyses were performed using R version 3.4.0 (2017-04-21).

Results

No significant differences in demographic or other patient characteristics were observed between the sugammadex and neostigmine groups (Table 1). With the exception of NMBAs and reversal drugs, no differences in anaesthetic and surgical characteristics were observed between the two groups (Table 2). Sugammadex was administered for reversal of moderate and deep NMB in 57.7% and 42.3% of cases, respectively. In the postoperative period, the sugammadex group showed significantly lower incidence of

hypoxemia, shorter PACU stay, and reduced ICU admissions (Table 2). No patient in either group exhibited clinical evidence of major postoperative complications.

Table 1
Patients' characteristics.

Characteristic	NEO (n = 175)	SUG (n = 175)	P-value
Sex, M/F, n (%)	117 (66.9)/58(33.1)	104 (59.4)/71 (40.6)	0.184
Age, yrs [IQR]	52 [40.5–63]	52 [43.5–60]	0.654
Height, cm [IQR]	170 [165–176]	170 [164–176]	0.355
Weight, kg [IQR]	70 [62–80]	68 [55–78]	0.186
BMI, kg/m ² [IQR]	24.22 [22-26.2]	23.6 [20.4–26.1]	0.194
ASA, II/III/IV, n (%)	34 (19.4)/137(78.3)/4 (2.3)	26 (14.9)/148(84.6)/1 (0.6)	0.197
Neurovascular disease, n (%)	6 (3.4)	10 (5.7)	0.444
Respiratory disease, n (%)	18 (10.3)	26 (14.9)	0.195
• Obstructive, n (%)	8 (4.6)	11 (6.3)	0.638
• Other, n (%)	10 (5.7)	15 (8.6)	0.407
Cardiovascular disease, n (%)	137 (78.3)	147 (84)	0.219
• Hypertension, n (%)	124 (70.9)	130 (74.3)	0.549
• Other, n (%)	13 (7.9)	17 (9.7)	0.529
Abdominal disease, n (%)	63 (36)	79 (45.1)	0.102
Impaired glucose tolerance, n (%)	25 (14.3)	30 (17.1)	0.557
Dyslipidaemia, n (%)	30 (17.1)	32 (18.3)	0.889
Other disease, n (%)	16 (9.1)	13 (7.4)	0.699
Previous KTx, n (%)	18 (10.3)	16 (9.1)	0.857

NMB: neuromuscular block; NEO: group of patients receiving neostigmine for reversal of cisatracurium-induced NMB; SUG: group of patients receiving sugammadex for reversal of rocuronium-induced NMB; M: male; F: female. BMI: body mass index; ASA: American Society of Anesthesiologists physical status; neurovascular disease: history of transient ischemic attack, stroke, cerebral hemorrhage; respiratory disease: history of asthma, chronic obstructive pulmonary disease, or other diseases (restrictive lung diseases); cardiovascular disease: history of coronary artery disease, arrhythmia, heart failure,

hypertension, disorders of the peripheral vascular system; abdominal disease: gastrointestinal disease (history of peptic ulcer, gastroesophageal reflux disease, irritable bowel syndrome, diverticular diseases, colitis, anal disease) and liver disease; other disease: rheumatic disease and musculoskeletal disease. Previous KTx: previous kidney transplantation. Data are expressed as median [interquartile range, IQR] or number, n (%).

Table 2
Perioperative period

Medications	NEO (n = 175)	SUG (n = 175)	P-value
Intraoperative period			
Intravenous anesthesia, n (%)	62 (35.4)	56 (32)	0.572
Inhalational anesthesia, n (%)			
• sevoflurane, n (%)	65 (37.1)	58 (33.1)	0.502
• desflurane, n (%)	48 (27.4)	61 (34.9)	0.166
Fentanyl, n (%)	67 (38.3)	72 (41.1)	0.662
Remifentanyl, n (%)	86 (49.1)	92 (52.6)	0.593
Ketamine, n (%)	20 (11.4)	15 (8.6)	0.476
Paracetamol, n (%)	153 (87.4)	159 (90.9)	0.391
Morphine, n (%)	27 (15.4)	25 (14.3)	0.881
Tramadol, n (%)	99 (56.6.4)	92(52.6.3)	0.520
Vasoactive drugs, n (%)	38 (21.7)	35 (20)	0.793
Droperidol, n (%)	39 (22.3.9)	42 (24)	0.800
Ondansetron, n (%)	149 (85.1)	141 (80.6)	0.321
Clonidine, n (%)	15 (8.6)	9 (5.1)	0.290
Pethidine, n (%)	10 (5.7)	7 (4.0)	0.620
Cisatracurium, mg [IQR]	36.9 [21.8–70.1]	0.0 [0.0–0.0]	< 0.001
Rocuronium, mg [IQR]	0.0 [0.0–0.0]	110.0 [60.0-220.0]	< 0.001
Atropine (%)	141 (80.6)	0.0 (0.0)	< 0.001
Neostigmine (%)	175.0 (100)	0.0 (0.0)	< 0.001
Neostigmine, µg/kg	29.9 [12.2–67.4]	0.0 [0.0–0.0]	< 0.001
Sugammadex 2 mg/kg (%)	0 (0.0)	101 (57.7)	< 0.001
Sugammadex 4 mg/kg (%)	0 (0.0)	74 (42.3)	< 0.001
Surgery, min [IQR]	185 [155-237.5]	180 [150–225]	0.116
Anesthesia, min [IQR]	235 [210-292.5]	240 [205–285]	0.589
Postoperative period			

Medications	NEO (n = 175)	SUG (n = 175)	P-value
SpO ₂ at T15, %	99 [98–99]	99 [98–100]	0.117
HR at T15, beats/min [IQR]	81.0 [71–91]	82 [72.5–92.5]	0.271
SBP at T15, mmHg [IQR]	140.0 [130-154.5]	145 [128.5-157.5]	0.503
DBP at T15, mmHg [IQR]	80.0 [71.0-87.5.5]	79 [70.0–88.0]	0.348
pH at T15 [IQR]	7.36 [7.33–7.4]	7.36 [7.33–7.39]	0.671
PaO ₂ at T15, mmHg [IQR]	88.6 [76-103.2]	89.2 [79.5-101.4]	0.253
PaCO ₂ at T15, mmHg [IQR]	39.6 [36.2–42.4]	39.7 [36.4–43.6]	0.207
Pain NRS > 3 at T15, n (%)	18 (10.3)	14 (8.0)	0.579
PONV NRS > 3 at T15, n (%)	13 (7.4)	8 (4.6)	0.368
Hypoxemia, n (%)	11 (6.3)	1 (0.6)	0.006
Antihypertensive drugs, n (%)	16 (9.1)	9 (5.1)	0.212
PACU stay, min [IQR]	90 [60–105]	70 [60.0–90.0]	< 0.001
ICU admission, n (%)	14 [8.0]	1 [0.6]	0.001

NMB: neuromuscular block; NEO: group of patients receiving neostigmine for reversal of cisatracurium-induced NMB; SUG: group of patients receiving sugammadex for reversal of rocuronium-induced NMB; vasoactive drugs: repeated administration of etilefrine or ephedrine, or dopamine infusion; surgery: time from skin incision to the placement of the last suture; anesthesia: time from tracheal intubation to tracheal extubation; PACU (post-anesthesia care unit): time from PACU admission to discharge to the surgical ward; ICU: intensive care unit; SpO₂: peripheral arterial blood oxygen saturation; PaO₂: arterial partial pressure of oxygen; PaCO₂: arterial partial pressure of carbon dioxide; HR: heart rate; SBP: systolic arterial blood pressure; DBP: diastolic arterial blood pressure; T15: 15 min after tracheal extubation; NRS: numeric rating scale; PONV: postoperative nausea and vomiting; hypoxemia: oxygen desaturation (SaO₂ < 90%) requiring treatment; antihypertensive drugs: clonidine, urapidil; amlodipine, labetalol; diltiazem. Data are expressed as median [interquartile range, IQR] or number, n (%).

Regarding perioperative kidney function, serum creatinine (596.0 [478.0-749.0] vs 639.0 [527.7–870.0] μmol/L, p = 0.0128) and serum urea (14.9 [10.8–21.6] vs 17.1 [13.1–22.0] mmol/L, p = 0.0486) were lower, while eGFR (8.0 [6.0–11.0] vs 8.0 [6.0–10.0], p = 0.0473) was higher in the sugammadex group than in the neostigmine group after surgery (Table 3, Fig. 1). Serum urea remained significantly lower in the first 3 postoperative days (Table 3). No differences in kidney function were observed between the moderate and deep groups of sugammadex patients (Table 3). The proportion of patients with an

increase in serum creatinine to $> 44 \mu\text{mol/L}$ was higher in the sugammadex group than in the neostigmine group (first postoperative day: 40 [22.9%] vs 33 [18.9%], $p = 0.430$; fifth postoperative day: (15 [8.6%] vs 14 [8.0%], $p = 1.0$). However, the need for postoperative dialysis was higher in the neostigmine group than in the sugammadex group (21 [12%] vs 18 [10.3%], $p = 0.734$).

Table 3
Perioperative kidney function.

Variable	Baseline	D0	D1	D2	D3	D4	D5
Creatinine (µmol/L) [IQR]							
NEO	753.0 [614.5-993.5]	639.0 [527.7-870.0]	558.0 [365.5-720.5]	397.0 [202.5-643.5]	253.0 [137.5-555.5]	190.0 [121.5-439.5]	170.0 [115.0-430.5]
SUG	759.0 [585.5-948.5]	596.0 [478.0-749.0]*	504.0 [370.0-658.0]	384.0 [170.0-596.5]	214.0 [126.5-496.5]	183.0 [117.0-433.5]	162.0 [107.5-379.0]
Creatinine (µmol/L) [IQR]							
SUG < 4 mg/kg (101 pts)	757.0 [592.0-944.0]	605.0 [502.0-744.0]	484.0 [367.0-642.0]	360.0 [170.0-611.0]	228.0 [134.0-500.0]	185.0 [126.0-437.0]	168.0 [121.0-399.0]
SUG ≥ 4 mg/kg (74 pts)	763.5 [573.0-953.0]	564.5 [461.5-798.5]	511.5 [378.5-680.5]	400.5 [173.5-569.0]	208.0 [119.7-494.0]	169.0 [104.7-422.0]	155.0 [100.0-362.0]
Urea (mmol/L) [IQR]							
NEO	18.7 [13.85-24.95]	17.1 [13.1-22.0]	17.5 [13.5-21.8]	17.9 [12.4-24.9]	16.4 [10.4-25.4]	15.8 [9.9-27.6]	14.7 [9.6-25.3]
SUG	17.6 [13.62-23.6]	14.9 [10.8-21.6]*	15.3 [11.3-19.8]*	15.9 [8.8-20.5]*	14.9 [7.5-20.7]*	14.2 [7.7-23.0]	12.9 [7.7-24.7]
Urea (mmol/L) [IQR]							
SUG < 4 mg/kg (101 pts)	17.44 [13.93-24.09]	15.48 [11.96-22.82]	15.9 [11.5-19.7]	16.4 [10.0-20.6]	14.7 [8-20.8]	14.4 [8.45-22.8]	14.37 [8.2-23.9]
SUG ≥ 4 mg/kg (74 pts)	17.6 [12.5-23.42]	14.3 [10.3-20.64]	14.45 [11.0-19.8]	14.7 [7.45-20.47]	15.1 [6.69-20.7]	13.35 [7.12-23.32]	12.5 [7.2-25.5]
eGFR [IQR]							
NEO	6.0 [5.0-8.0]	8.0 [6.0-10.0]	9.0 [7.0-14.0]	13.0 [7.5-29.0]	21.0 [9.0-43.5]	31.0 [11.0-51.0]	35.0 [12.2-53.7]

Variable	Baseline	D0	D1	D2	D3	D4	D5
SUG	6.0 [5.0–8.0]	8.0 [6.0–11.0] *	10.0 [7.0–14.5]	14.0 [8.0–36.0]	23.0 [10.0–52.5]	32.0 [12.0–59.5]	36.0 [14.0–61.0]
eGFR [IQR]							
SUG < 4 mg/kg (101 pts)	6.0 [5.0–8.0]	8.0 [6.0–11.0]	10.0 [7.0–15.0]	15.0 [8.0–38.0]	23.0 [10.0–52.0]	32.0 [13.0–55.0]	36.0 [14.0–56.0]
SUG ≥ 4 mg/kg (74 pts)	6.0 [5.0–8.0]	8.0 [6.0–10.0]	9.0 [6.0–12.75]	14.0 [8.0–33.75]	26.0 [10.0–54.0]	33.0 [12.0–63.75]	37.0 [15.0–64.0]

NMB: neuromuscular block; NEO: group of patients receiving neostigmine for reversal of cisatracurium-induced NMB; SUG: group of patients receiving sugammadex for reversal of rocuronium-induced NMB; SUG < 4 mg/kg a SUG: ≥4 mg/kg; sugammadex dose per kg of body weight for reversal of moderate or deep NMB, respectively; baseline: value before kidney transplantation; D0-D5: values obtained the day of kidney transplantation (D0) and in each of the following five postoperative days (D1-D5); eGRF: estimated glomerular filtration rate; creatinine and urea: serum creatinine and serum urea; eGRF: estimated glomerular filtration rate. Data are expressed as median [interquartile range, IQR]. (*) = significant p-value (< 0.05) at intergroups analysis.

Body weight (CC = 0.282; p < 0.0001), height (CC = 0.281; p < 0.0001), body mass index (BMI) (CC = 0.165; p = 0.0019), preoperative serum creatinine (CC = 0.779; p < 0.0001), and neostigmine (CC=-0.265; p < 0.001) were correlated with postoperative serum creatinine (Fig. 2). No significant correlations were observed with other drugs involved in NMB management (Fig. 2).

During fitted multiple linear regression analysis, body weight (EC = 3.092; SE = 0.988; t = 3.127; p = 0.0019) and preoperative serum creatinine (EC = 0.706; SE = 0.027; t=-25.64; p < 0.0001) were the only variables associated with a higher level of postoperative serum creatinine, while rocuronium was associated with a lower level of postoperative serum creatine (EC=-0.607; SE = 0.227; t=-2.666; p = 0.008).

Discussion

In this study, sugammadex administered to reverse a rocuronium-induced NMB has been shown to improve recovery after kidney transplantation. Compared to the cisatracurium-neostigmine strategy, the rocuronium-sugammadex strategy resulted in lower incidence of postoperative respiratory events, faster discharge to the surgical ward, lower ICU admission, and better values of kidney function after surgery.

In patients with renal impairment, sugammadex was shown to effectively reverse both moderate (Staals et al. 2008; Staals et al. 2010) and deep (Cammu et al. 2012; de Souza et al. 2015; Panhuizen et al. 2015) rocuronium-induced NMB. No complications definitely, probably, or possibly related to the reversal drug have been reported (Staals et al. 2008; Staals et al. 2010; Cammu et al. 2012; de Souza et al. 2015;

Panhuizen et al. 2015). In patients undergoing kidney transplantation, successful use of sugammadex for reversal of moderate rocuronium-induced NMB has been reported by retrospective observational studies (Unterbuchner et al. 2016; Ono et al 2018; Arslantas et al. 2019; Adams et al. 2020; Peredes et al. 2020; Vargas et al. 2020). Potential effects of sugammadex, or sugammadex-rocuronium complex, on renal function and the risk of postoperative recurrence of NMB are the main concerns about the rocuronium-sugammadex strategy in subjects with ESRD, including those undergoing kidney transplantation.

After administration, sugammadex (and sugammadex-rocuronium complexes) is renally excreted (Bom et al. 2009; Staals et al. 2010.). In a pharmacokinetic study, excretion of (14)C-labelled sugammadex was rapid, with around 70% of the dose excreted within 6 h and around 90% within 24 h. Consequently, the major route of elimination of rocuronium changes from the hepatic to the renal route (Peeters et al. 2011). In patients with ESRD, total plasma clearance of sugammadex was 17 times lower and mean elimination half-life was 16 times higher in the renal failure group compared to control (Staals et al. 2010). Therefore, administration of sugammadex after rocuronium results in lengthened exposure of renal glomeruli and tubules to sugammadex and sugammadex-rocuronium complexes, leading to hypothesize their role in the renal impairment after surgery (Bostan et al. 2011). However, cyclodextrins are highly water-soluble cyclic oligosaccharides without intrinsic biological activity; it is therefore unlikely that side effects will occur after administration (Staals et al. 2011). Toxicity studies on γ -cyclodextrins have shown that the drugs are well tolerated and elicit no toxicological effects (Munro et al. 2004). Also, sugammadex, belonging to the family of γ -cyclodextrins, is biologically inactive and, administered at the recommended dose, has been shown to be well tolerated in patients with renal impairment (Staals et al. 2008; Staals et al. 2010; Cammu et al. 2012; de Souza et al. 2015; Adams et al. 2020; Peredes et al. 2020). In an experimental study, only sugammadex administered at a higher dose (96 mg/kg) than that recommended (≤ 16 mg/kg) resulted in a significant increase of histopathological changes in the rat kidney (dilatation, vascular vacuolation and hypertrophy, lymphocyte infiltration, and tubular cell sloughing) compared to the control group (Bostan et al. 2011). Similar findings were reported in streptozotocin-induced diabetic rats. Diabetic nephropathy predisposes to changes in kidney tissues including inflammation, degeneration, necrosis, tubular dilatation, tubular cell degeneration, dilatation in Bowman's space, tubular hyaline casts, and lymphocyte infiltration. In renal tissue samples, a significant increase in histopathological changes was found after sugammadex 96 mg/kg but not sugammadex 16 mg/kg treatment compared to diabetic control (Kip et al. 2015). These results suggest that, at recommended doses, sugammadex doesn't significantly impact renal function (Bostan et al. 2011), also in case of diabetic nephropathy (Kip et al. 2015). In a dose-finding and safety study in adult patients, abnormal levels of N-acetyl-glucosaminidase were only found in 5 of 20 patients included in the intent-to-treat population and safety population (Sorgenfrei et al. 2006). However, changes in urinalysis were reported in the active treatment groups (sugammadex 0.5-4.0 mg/kg) as well as in the placebo group but were not considered to be clinically relevant (Sorgenfrei et al. 2006).

The impact on renal function of sugammadex compared to neostigmine for reversal of NMB also deserves consideration. A study designed to evaluate the cytotoxic, genotoxic, and apoptotic effects of

different dosages of both reversal drugs on human embryonic renal (HEK-293) cells showed that neostigmine administered in vitro at 50, 100, 250, and 500 µg/mL had greater cytotoxic, genotoxic, and apoptotic effects on HEK-293 cells than the equivalent dosages of sugammadex (Büyükfırat et al. 2018). In adult patients undergoing desflurane/opioid anaesthesia that received neostigmine 40 µg/kg and sugammadex 4 mg/kg to reverse rocuronium-induced NMB, renal glomerular filtration and tubular functions were minimally affected. However, these effects were greater with neostigmine than with sugammadex. No significant changes were observed for serum creatinine and urea levels between the two groups. Instead, in urinalysis, the postoperative value of cystatin C, a specific marker of glomerular function, was found to be significantly higher in the neostigmine group compared to the sugammadex group (Isik et al. 2016). Comparing the rocuronium-sugammadex strategy to the cisatracurium-neostigmine strategy in adult patients, significant differences were found only in urinalysis, with N-acetylglucosaminidase higher in the rocuronium-sugammadex group, and β_2 -microglobulin higher in the cisatracurium-neostigmine group (Flockton et al 2008).

A comparison of the rocuronium-sugammadex and cisatracurium-neostigmine strategies was retrospectively evaluated in kidney transplantation, but the sample size was not large enough to draw a conclusion on the impacts of sugammadex and neostigmine on renal function in such population of patients, and no data are included on sugammadex administered to reverse deep rocuronium-induced NMB (Vargas et al. 2020). This study confirmed the advantage of the rocuronium-sugammadex over the cisatracurium-neostigmine strategy not only in improving postoperative kidney function (Vargas et al. 2020), but also in promoting a better general recovery, independently from the level of NMB at the end of surgery. This may be explained by different impacts of the two reversal drugs on renal function (Munro et al. 2004; Sorgenfrei et al. 2006; Flockton et al 2008; Staals et al 2011; Bostan et al. 2011; Kip et al. 2015; Isik et al. 2016; Büyükfırat et al. 2018; Vargas et al. 2020), a restoration of glomerular filtration after surgery that minimizes the stasis of the sugammadex (and rocuronium-sugammadex complex) in the glomeruli and tubules (Bostan et al. 2011; Kip et al. 2015; Vargas et al. 2020), and a potential protective effect of sugammadex against ischemia-reperfusion injury (Vargas et al. 2020). In an experimental study, sugammadex 16 mg/kg and 100 mg/kg, administered to evaluate the benefit of cyclodextrins against transient global cerebral ischemia, showed a dose-dependent neuroprotective effect in a transient global cerebral ischemia/reperfusion rat model (Ozbilgin et al. 2016). In the postoperative period, the transient increase of serum urea, which peaked on the third day after surgery, may be due to the catabolic effects of corticosteroids administered perioperatively to prevent graft rejection and of diuretics (Vargas et al. 2020).

Serum creatinine level significantly decreased over time after kidney transplantation. The recipient's age was negatively associated with the postoperative serum creatinine values. No significant association was found between the serum creatinine levels and the recipient's BMI, gender, or history of dialysis (Younespour et al. 2016). On the basis of our analysis, postoperative serum creatinine significantly depends on preoperative values. Most importantly, the drugs involved in NMB management had no effects. A positive association has been shown between serum creatinine levels and graft failure, which

means that graft failure is more likely to occur in patients with higher postoperative serum creatinine levels (Younespour et al. 2016; Maraghi et al. 2016). A one-unit increase in the serum creatinine level was found to be associated with a four (Younespour et al. 2016) or five times (Maraghi et al. 2016) higher risk of graft failure.

A high affinity of rocuronium to sugammadex allows the guest-host complex to exist in equilibrium with a very high association rate (an association constant of 10^7 M^{-1}) and a very low dissociation rate, so the complex is tight and recurrence of NMB is highly unlikely (Bom et al. 2009). The absence of recurrences of NMB observed in our large cohort of patients supports the safety of the rocuronium-sugammadex strategy in kidney transplantation and confirms the findings from other observational studies. Ono et al. reported a successful use of sugammadex in 99 consecutive patients undergoing kidney transplantation (Ono et al. 2018), Adams et al. in 48 patients (Adams et al. 2020), and Vargas et al. in 30 patients (Vargas et al. 2020), without recurrences of NMB. Interestingly, among 158 patients with ESRD undergoing a surgical procedure, sugammadex was administered to 24 patients (18%) who had initially been reversed with a standard dose of neostigmine (70 $\mu\text{g}/\text{kg}$ up to a maximum dose of 5 mg) for residual NMB, with immediate and full reversal of muscle strength loss and successful tracheal extubation at the end of surgery (Adams et al. 2020). A more favourable recovery after sugammadex compared to neostigmine is supported by the literature. Recovery to train-of-four ratio (TOFR) > 1.0 is recommended when acceleromyography is used (Eikermann et al. 2007). Although TOFR ≥ 0.9 indicates adequate recovery from NMB, it does not necessarily mean that neuromuscular function has returned to normal and may increase the risk of upper airway obstruction, hypoventilation, hypoxia, and other postoperative respiratory complications (Eikermann et al. 2007; Blobner et al. 2020). Tracheal extubation in patients with TOFR > 0.95 has been shown to reduce the adjusted risk of postoperative pulmonary complications by 3.5% compared to extubation at TOFR > 0.9 (Blobner et al. 2020). Both quantitative monitoring of neuromuscular function and an appropriate dosage of reversal drug titrated to the level of NMB concur with a full reversal (TOFR ≥ 1.0) and an improvement of patient outcomes (Eikermann et al. 2007; Blobner et al. 2020). Compared to neostigmine, sugammadex has been associated with lower risk of postoperative complications (Carron et al. 2016) and a better recovery profile that allows faster discharge from the operating theatre and PACU (Carron et al. 2020) and reduced risk of ICU admission (Carron et al. 2016).

This study has two main limitations. First, it is not a randomized controlled study and therefore has the drawbacks of all observational studies. Second, more specific markers (e.g., cystatin C, N-acetylglucosaminidase; α_1 -microglobulin; β_2 -microglobulin) were not available for a targeted analysis of postoperative renal function.

In conclusion, sugammadex should be considered for reversal of rocuronium-induced NMB in patients undergoing kidney transplantation.

Abbreviations

aOR: Adjusted odds ratio

BMI: Body mass index

CC: Correlation coefficient

CrCl: Creatinine clearance

DBP: Diastolic arterial blood pressures

EC: Estimate coefficient

eGFR: Estimated glomerular filtration rate

ESRD: End-stage renal disease

HR: Heart rate

ICU: Intensive care unit

NMB: Neuromuscular block

NMBA: Neuromuscular block agent

NRS: Numeric rating scale

PACU: Post-anaesthesia care unit

PaCO₂: Arterial partial pressures of carbon dioxide

PaO₂: Arterial partial pressures of oxygen

PONV: Postoperative nausea and vomiting

SaO₂: Peripheral arterial blood oxygen saturation

SBP: Systolic arterial blood pressure

SE: Standard error

STROBE: STrengthening the Reporting of Observational studies in Epidemiology

TOFR: Train-of-four ratio

Declarations

Ethics approval and consent to participate: This retrospective observational study was approved by Institutional Review Board (Ethics Committee in Clinical Research-CESC of Padova, Italy, prot.n.42587, 16 July 2020), which waived the requirement to obtain patients' written informed consent.

Consent for publication. Not applicable

Availability of data and materials. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests. Carron M. has received payments for lectures from Merck Sharp & Dohme (MSD), Italy. Other authors have no interests to disclose regarding this study.

Funding. Not applicable

Author contributions. **CM:** conceptualization, methodology, investigation, data curation, formal analysis, validation, writing- original draft preparation, and writing – review and editing, final approval. **AG, PE:** conceptualization, methodology, investigation, data curation, formal analysis, validation, and writing – review and editing, final approval. **DCA, FP, LF, SM, DBC, DBM, NF, SC, FL, NP:** methodology, formal analysis, validation, and writing – review and editing, final approval.

Acknowledgements. Not applicable

Authors' informations (optional). Not applicable

References

1. Adams DR, Tollinche LE, Yeoh CB, Artman J, Mehta M, Phillips D, et al. Short-term safety and effectiveness of sugammadex for surgical patients with end-stage renal disease: a two-centre retrospective study. *Anaesthesia* 2020;75:348–352.
2. Arslantas R, Cevik BE. Retrospective Investigation of Grafted Kidney Function After Reversal of Neuromuscular Blockade Using Neostigmine or Sugammadex. *Transplant Proc* 2019;51:2265–2267.
3. Blobner M, Hunter JM, Meistelman C, Hoefl A, Hollmann MW, Kirmeier E, et al. Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data. *Br J Anaesth* 2020;124:63–72.
4. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. *J Crit Care.* 2009;24:29–35.
5. Bostan H, Kalkan Y, Tomak Y, Tumkaya L, Altuner D, Yılmaz A, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex and resulting histopathological effects in rat kidneys. *Ren Fail* 2011;33:1019-24.
6. Büyükfırat E, Koyuncu İ, Karahan MA, Binici O, Altay N, Kirit A, et al. Comparison of the cytotoxic, genotoxic and apoptotic effects of Sugammadex and Neostigmine on human embryonic renal cell (HEK-293). *Cell Mol Biol (Noisy-le-grand)* 2018;64:74–78.

7. Cammu G, Van Vlem B, van den Heuvel M, Stet L, el Galta R, Eloot S, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. *Br J Anaesth* 2012;109:382 – 90.
8. Carron M, Zarantonello F, Tellaroli P, Ori C. Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. *J Clin Anesth* 2016;35:1–12.
9. Carron M, Baratto F, Zarantonello F, Ori C. Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center. *Clinicoecon Outcomes Res* 2016;8:43 – 5
10. Carron M, Linassi F, De Cassai A. Role of sugammadex in accelerating postoperative discharge: An updated meta-analysis. *J Clin Anesth* 2020;65:109895.
11. De Gasperi A, Feltracco P, Ceravola E, Mazza E. Pulmonary complications in patients receiving a solid-organ transplant. *Curr Opin Crit Care* 2014;20:411-9.
12. Della Rocca G, Pompei L, Coccia C, Costa MG, Cecchini V, Vilardi V, et al. Atracurium, cisatracurium, vecuronium and rocuronium in patients with renal failure. *Minerva Anesthesiol* 2003;69:605 – 11.
13. de Souza CM, Tardelli MA, Tedesco H, Garcia NN, Caparros MP, Alvarez-Gomez JA, de Oliveira Junior IS. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial. *Eur J Anaesthesiol* 2015;32:681-6.
14. EMA. Bridion (sugammadex sodium) 100 mg/mL: summary of product characteristics. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000885/WC500052310.pdf (Accessed January 25, 2021)
15. Eikermann M, Vogt FM, Herbstreit F, Vahid-Dastgerdi M, Zenge MO, Ochterbeck C, et al. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. *Am J Respir Crit Care Med* 2007;175:9–15.
16. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. *Br J Anaesth* 2008;100:622 – 30.
17. Gameiro J, Agapito Fonseca J, Jorge S, Lopes JA. Acute Kidney Injury Definition and Diagnosis: A Narrative Review. *J Clin Med* 2018;7.
18. Isik Y, Palabiyik O, Cegin BM, Goktas U, Kati I. Effects of Sugammadex and Neostigmine on Renal Biomarkers. *Med Sci Monit* 2016;22:803-9.
19. Kellar CA. Solid organ transplantation overview and delection criteria. *Am J Manag Care* 2015;21:S4-S11.
20. Kheterpal S, Vaughn MT, Dubovoy TZ, Shah NJ, Bash LD, Colquhoun DA, et al. Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. *Anesthesiology* 2020;132:1371–1381.

21. Kip G, Turgut HC, Alkan M, Aydin ME, Erbatur ME, Kiraz HA, et al. The effects of low and high doses of sugammadex on kidney tissue in streptozotocin-induced diabetic rats. *Bratisl Lek Listy* 2015;116:746 – 50.
22. Kirmeier E, Eriksson LI, Lewald H, Jonsson Fagerlund M, Hoefl A, et al.; POPULAR Contributors. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. *Lancet Respir Med* 2019;7:129–140.
23. Kork F, Balzer F, Spies CD, Wernecke KD, Ginde AA, Jankowski J, et al. Minor Postoperative Increases of Creatinine Are Associated with Higher Mortality and Longer Hospital Length of Stay in Surgical Patients. *Anesthesiology* 2015;123:1301-11.
24. Maraghi E, Rahimi Foroushani A, Younespour S, Rostami Z, Einollahi B, Eshraghian MR, et al. Longitudinal Assessment of Serum Creatinine Levels on Graft Survival After Renal Transplantation: Joint Modeling Approach. *Nephrourol Mon* 2016;8:e37666.
25. Martinez BS, Gasanova I, Adesanya AO. Anesthesia for Kidney Transplantation-A Review. *J Anesth Clin Res* 2013; 4:270.
26. Miskovic A, Lumb AB. Postoperative pulmonary complications. *Br J Anaesth* 2017;118:317–334.
27. Mittel AM, Wagener G. Anesthesia for Kidney and Pancreas Transplantation. *Anesthesiol Clin* 2017;35:439–452.
28. Munro IC, Newberne PM, Young VR, Bär A. Safety assessment of gamma-cyclodextrin. *Regul Toxicol Pharmacol* 2004;39:S3-13.
29. Ono Y, Fujita Y, Kajiura T, Okawa H, Nakashima J, Isobe H, et al. Efficacy and safety of sugammadex in patients undergoing renal transplantation. *JA Clin Rep* 2018;4:56.
30. Ozbilgin S, Yilmaz O, Ergur BU, Hancı V, Ozbal S, Yurtlu S, et al. Effectiveness of sugammadex for cerebral ischemia/reperfusion injury. *Kaohsiung J Med Sci* 2016;32:292–301.
31. Panhuizen IF, Gold SJ, Buerkle C, Snoeck MM, Harper NJ, Kaspers MJ, et al. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg⁻¹ for reversal of deep neuromuscular blockade in patients with severe renal impairment. *Br J Anaesth* 2015;114:777 – 84.
32. Paredes S, Porter SB, Porter IE 2nd, Renew JR. Sugammadex use in patients with end-stage renal disease: a historical cohort study. *Can J Anaesth* 2020;67:1789–1797.
33. Peeters P, Passier P, Smeets J, Zwiers A, de Zwart M, van de Wetering-Krebbbers S, et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. *Biopharm Drug Dispos* 2011;32:159 – 67.
34. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. *Anesthesiology* 2006;104:667 – 74.
35. Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. *Br J Anaesth* 2008;101:492-7.

36. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. *Br J Anaesth* 2010;104:31 – 9.
37. Staals LM, de Boer HD, van Egmond J, Hope F, van de Pol F, Bom AH, et al. Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats. *J Anesth* 2011;25:241-6.
38. Unterbuchner C. Use of rocuronium and sugammadex in renal transplantation: Problems that must be considered. *Eur J Anaesthesiol* 2016;33:690-1.
39. Vargas M, Buonanno P, Sica A, Sabatella E, D'Alessio FP, Alfieri S, et al. Effects of Sugammadex Plus Rocuronium vs Neostigmine Plus Cisatracurium During Renal Transplantation on Graft Function: A Retrospective, Case-Control Study. *Transplant Proc* 2020:S0041-1345(20)30545-5.
40. Wagener G, Bezinover D, Wang C, Kroepfl E, Diaz G, Giordano C, et al. Fluid Management During Kidney Transplantation: A Consensus Statement of the Committee on Transplant Anesthesia of the American Society of Anesthesiologists. *Transplantation*. 2020 Dec 14. doi: 10.1097/TP.0000000000003581.
41. Younespour S, Rahimi Foroushani A, Maraghi E, Rostami Z, Einollahi B, Eshraghian MR, et al. Longitudinal Serum Creatinine Levels in Relation to Graft Loss Following Renal Transplantation: Robust Joint Modeling of Longitudinal Measurements and Survival Time Data. *Nephrourol Mon* 2016;8:e39292.

Figures




Figure 1

Box plots comparing sugammadex to neostigmine on kidney function before and after surgery. Boxes represent the median and IQR. “Whiskers” (minimum and maximum marks) represent values 1.5 times the IQR [(1st quartile–1.5×IQR) and (3rd quartile+1.5×IQR)]. IQR: interquartile range, p: p-value with significance set at <0.05; NEO: group of patients receiving neostigmine for reversal of cisatracurium-induced neuromuscular block (NMB); ; SUG: group of patients receiving sugammadex for reversal of rocuronium-induced NMB; PRE: baseline value (before kidney transplantation); POST: first measurement obtained the day of kidney transplantation; creatinine and urea: serum creatinine and serum urea; eGFR: estimated glomerular filtration rate.




Figure 2

Correlation between patients' characteristics, preoperative serum creatinine and anaesthetic drugs with postoperative serum creatinine. Drugs involved in neuromuscular block management were considered. POST: first measurement of creatinine obtained after surgery the day of kidney transplantation; mg: total dose; mg/kg: dose in microgram (μg) or milligram (mg) per kilogram (kg) body weight. BMI: body mass index. Spearman's rank correlation tests each analysis. CC: correlation coefficient; p: p-value with significance set at <0.05.